Article
Rifaximin for sickle cell disease
12 Sept 2019
Abstract excerpt
Patients with sickle cell disease (SCD) suffer recurrent painful vaso-occlusive crisis (VOC), poor quality of life and a shortened lifespan. Although hydroxyurea and blood transfusion remain the mainstay of SCD therapy, the only cure currently available is allogeneic stem cell transplant (allo-SCT). However, many barriers prevent allo-SCT from being widely offered to adult SCD patients. The SCD patients most in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
